Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 3

The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey

Pages
587–595
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our pSS cohort, the risk for ovarian cancer was found to be increased, which has not been previously reported in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The aim of this study is to determine the risk of cancer in patients with primary Sjögren syndrome (pSS) from a single center in Turkey.
📊
Key Findings & Data:The incidence of cancer for general population was obtained from GLOBOCAN 2018.
💡
Conclusion & Impact:In our pSS cohort, the risk for ovarian cancer was found to be increased, which has not been previously reported in the literature.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: The aim of this study is to determine the risk of cancer in patients with primary Sjögren syndrome (pSS) from a single center in Turkey. Methods: Clinical data of the subjects with pSS were retrospectively analyzed. The incidence of cancer for general population was obtained from GLOBOCAN 2018. Age- and sex-specific standardized incidence ratios (SIR) of solid and hematological cancers were calculated compared with the general population. Results: Four hundred thirty patients with pSS were included in the study. The majority of the patients were female (n = 396, 92.1%), and the mean age was 58.6 ± 12.0 years. Thirty-four patients (7.9 %) were diagnosed with cancer (26 solid and 8 hematological) during follow-up. The SIR for all cancers was 2.45 (95% CI, 1.625–3.275). The SIR was 2.42 (95% CI, 1.542–3.298) for solid cancers and 8.42 (95% CI, 2.394 - 14.446) for hematological cancers. The most diagnosed malignancies were breast cancer (n = 6), ovarian cancer (n = 6), and non-Hodgkin lymphoma (NHL) (n = 4). There was an increased risk for ovarian cancer (SIR 12.76, 95% CI, 2.545–22.975). The SIR values were 2.08 (95% CI, 0.419-3.741) and 10.81 (95% CI, 0.216–21.404) for breast cancer and NHL, respectively. Conclusion: The risk of hematological and solid cancers was higher in the patients with pSS when compared to general population. In our pSS cohort, the risk for ovarian cancer was found to be increased, which has not been previously reported in the literature.

🔖

Cite This Article

ERBASAN, F., ÖĞÜT, T. S., ÇELİK, E., YAZISIZ, V., ASLAN, B., TERZİOĞLU, M. E., DİLBİL, M. (2022). The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 3, 587–595. https://ajindex.com/articles/609254

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Fox RI. Sjögren’s syndrome. Lancet 2005
  2. doi:10.1016/S0140-6736(05)669905 2. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A et al. GEMESS Study Group. Primary Sjögren syndrome in Spain = clinical and immunologic expression in 1010 patients. Medicine (Baltimore)2008 Jul
  3. 87(4):210-219. doi: 10.1097/ MD.0b013e318181e6af 3. Yazisiz V, Avci AB, Erbasan F, Kiriş E, Terzioğlu E. Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren’s syndrome: a retrospective analysis. Rheumatolology International 2009
  4. 29(4):403-409. doi: 10.1007/s00296-008-0698-1 4. Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F et al. Lung involvement in patients with primary Sjögren’s syndrome: what are the predictors? Rheumatology International 2010
  5. doi: 10.1007/s00296-009-1152-8 5. Bombardieri M, Argyropoulou OD, Ferro F, Coleby R, Pontarini E et al. One year in review 2020: pathogenesis of primary Sjögren’s syndrome. Clinical and Experimental Rheumatology 2020
  6. 38(4): Suppl 126:3-9 6. Sarigul M, Yazisiz V, Bassorgun CI, Ulker M, Avci AB et al. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren’s syndrome. Lupus 2010
  7. 19(2):138-145. doi: 10.1177/0961203309348234 7. Yazisiz V, Göçer M, Erbasan F, Uçar İ, Aslan B et al. Survival analysis of patients with Sjögren’s syndrome in Turkey: a tertiary hospital-based study. Clinical Rheumatology 2020
  8. 39(1):233-241. doi: 10.1007/s10067-019-04744-6 8. Zhang W, Feng S, Yan S, Zhao Y, Li M et al. Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology (Oxford)2010Mar
  9. 49(3):571-577. doi: 10.1093/rheumatology/kep404. Epub 2009 Dec 29 9. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2014 Jun
  10. 73(6): 1151-1156. doi: 10.1136/annrheumdis-2013-203305. Epub 2013 May 17 10. Brom M, Moyano S, Gandino IJ, Scolnik M, Soriano ER. Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina. Rheumatolology International 2019 Oct
  11. 39(10): 1697-1702. doi: 10.1007/s00296-019-04433-2. Epub 2019 Aug 30 11. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP et al. Increased risk of lymphoma in sicca syndrome. Annals of Internal Medicine 1978
  12. 888–892 12. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O et al. Autoimmu